Alkem Laboratories Limited announced on Friday, September 26, that it has formally entered into a Business Transfer Agreement with its wholly owned subsidiary, Alkem Wellness Limited, for the transfer of its trade generics business.
The transaction, structured as a slump sale on a going concern basis, will become effective from October 1, 2025. The move was earlier communicated to the stock exchanges in December 2024, and has now been finalized with the signing of the agreement.
Alkem Wellness, incorporated in India, will now take charge of the trade generics business, allowing the parent company to focus on its core segments while retaining full ownership through the subsidiary.
The company confirmed that the disclosure was made under Regulation 30 of SEBI (LODR) Regulations, 2015 and the update is available on its official website.
